E
Shares of Xoma (XOMA) are trading down 77% at Wednesday’s close after reporting failed results of its phase 3 trial in patients with Behcet’s disease Uveitis — a rare eye disease. The phase 3 trial is known as the EYEGUARD-B trial run by a French Pharmaceutical company known as Servier. Patients in the study were…